DrugPipeline.net has announced the addition of “Uveal Melanoma - Pipeline Review, H1 2018” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 05/25/2018 --Uveal Melanoma - Pipeline Review, H1 2018, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights
Uveal Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 12, 10, 1 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 185 pages "Uveal Melanoma - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Uveal Melanoma - Overview, Uveal Melanoma - Therapeutics Development, Uveal Melanoma - Therapeutics Assessment, Uveal Melanoma - Companies Involved in Therapeutics Development, Uveal Melanoma - Drug Profiles, Uveal Melanoma - Dormant Projects, Appendix. This report Covered Companies - Aeglea BioTherapeutics Inc, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, Celldex Therapeutics Inc, Cleveland BioLabs Inc, Delcath Systems Inc, Eli Lilly and Co, Iconic Therapeutics Inc, Immunocore Ltd, Iovance Biotherapeutics Inc, Novartis AG, PEP-Therapy SAS, Pfizer Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Syndax Pharmaceuticals Inc, Tesaro Inc, Viralytics Ltd.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/uveal-melanoma-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - https://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Bronchiectasis - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/bronchiectasis-pipeline-review-h1-2018

Women Infertility - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/women-infertility-pipeline-review-h1-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

Press Contact:
Mr. Sudeep Chakravarty
Director - Operations
DrugPipeline.net
https://www.drugpipeline.net
Tel USA: +1-302-703-9904